NCT07015398View on ClinicalTrials.gov

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

September 12, 2025

Study Completion Date

September 26, 2025

Conditions

Healthy Participants

Interventions

DRUG

NAL ER

Oral tablets

DRUG

Pirfenidone

Oral tablets

DRUG

Nintedanib

Oral capsules

Trial Locations (1)

33172

Clinical Pharmacology of Miami, Miami

Sponsors

Lead Sponsor

Trevi Therapeutics

All Listed Sponsors

lead

Trevi Therapeutics

INDUSTRY